EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 25 January 2024

Cardiovascular disease: LSE-report highlights life-saving potential of secondary prevention

Cardiovascular disease: LSE-report highlights life-saving potential of secondary prevention...
23 January 2024

Cardiovascular disease (CVD) is the number one killer in Europe, but a new study by the London School of Economics and Political Science (LSE) shows the opportunity to save hundreds of thousands lives. The report, commissioned by EFPIA, features six recommendations that can reduce the risk of fatal heart attacks and strokes in people living with CVD, by following medical guidelines.

“There is a huge opportunity to address reversible risk factors in people who are already living with cardiovascular disease,” said Nathalie Moll, Director-General of EFPIA. “If existing evidence-based treatment targets and recommendations are followed, the impact will be profound.”

EFPIA response to the adoption of the EMA Fees Regulation
23 January 2024

EFPIA welcomes the adoption of the EMA Fees regulation by the Council and the Parliament. Read more

Blogs

From theory to therapy – MSD Policy Passport on Pharmaceutical Innovation
22 January 2024 - Boris Azaïs

Policy makers are in the driving seat. Their decisions play a key role in the creation and sustainability of Europe’s... Read more

Events

Real-World data, Machine learning and Deep analytics in rare diseases
26 January 2024 (Virtual event)

EJP RD - European Joint Programme on Rare Diseases Read more

ACCELERATE 2024 Paediatric Oncology Conference
08 February 2024 (Brussels and virtually)

Join us to advance paediatric oncology drug development. Read more

Getting to the heart of the matter: improving cardiovascular health in Europe
20 February 2024 (Virtual event)

Join us to be at the forefront of shaping cardiovascular health management in the EU. Read more

Digitally-enabled healthcare: Is our ecosystem on track?
07 March 2024 (Brussels and online)

Organised by the EU Health Coalition. Read more

We are hiring!

Join the EFPIA team! We have 3 positions open:
🔵 Assistant Manager Communications
🟣 Vaccines Europe EU Project Manager
🟢 Vaccines Europe Public Affairs Intern

Check our website for more details and apply now.

What we are reading

Game-changing trial for children with tumours being established thanks to EU-PEARL
On 24 January 2024 (IHI)

The Children’s Tumor Foundation and the Global Coalition for Adaptive Research are making EU-PEARL’s model for a... Read more

Impact of the EU's General Pharmaceutical Legislation on Europe’s innovation ecosystem and...
On 24 January 2024 (Europabio)

This study highlights the consequences of the General Pharmaceutical Legislation for EU patients and economies within... Read more

Healthcare through patient's eyes: The next generation of healthcare performance indicators...
On 24 January 2024 (OECD)

Preliminary results from the PatientReported Indicator Surveys (PaRIS)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu